Compare CDZI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZI | FHTX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 360.8M |
| IPO Year | N/A | 2020 |
| Metric | CDZI | FHTX |
|---|---|---|
| Price | $5.25 | $5.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 925.0K | 163.7K |
| Earning Date | 03-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,979,000.00 | ★ $24,518,000.00 |
| Revenue This Year | $58.18 | $40.91 |
| Revenue Next Year | $32.89 | $11.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.33 | N/A |
| 52 Week Low | $2.13 | $2.95 |
| 52 Week High | $6.96 | $6.95 |
| Indicator | CDZI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 50.49 |
| Support Level | $4.69 | $5.11 |
| Resistance Level | $5.09 | $5.74 |
| Average True Range (ATR) | 0.38 | 0.38 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 38.06 | 52.81 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.